Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTGX Stock Forecast 2025-2026
$44.41
Current Price
$2.71B
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PTGX Price Targets
+84.6%
To High Target of $82.00
+55.4%
To Median Target of $69.00
-7.7%
To Low Target of $41.00
PTGX Price Momentum
+3.4%
1 Week Change
-3.0%
1 Month Change
+39.0%
1 Year Change
+15.1%
Year-to-Date Change
-26.7%
From 52W High of $60.60
+64.5%
From 52W Low of $27.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Protagonist (PTGX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PTGX and similar high-potential opportunities.
Latest PTGX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, PTGX has a bullish consensus with a median price target of $69.00 (ranging from $41.00 to $82.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $44.41, the median forecast implies a 55.4% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Julian Harrison at BTIG, suggesting a 7.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTGX Analyst Ratings
9
Buy
1
Hold
0
Sell
PTGX Price Target Range
Low
$41.00
Average
$69.00
High
$82.00
Current: $44.41
Latest PTGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $80.00 |
| Mar 28, 2025 | Wedbush | Yun Zhong | Outperform | Reiterates | $70.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $80.00 |
| Mar 11, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $76.00 |
| Mar 11, 2025 | BMO Capital | Etzer Darout | Outperform | Reiterates | $72.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $54.00 |
| Mar 10, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $61.00 |
| Mar 4, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $57.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $54.00 |
| Feb 24, 2025 | Goldman Sachs | Neutral | Maintains | $38.00 | |
| Feb 24, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $54.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $50.00 |
| Feb 7, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $58.00 |
| Feb 4, 2025 | JP Morgan | Brian Cheng | Overweight | Maintains | $53.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $50.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $62.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $50.00 |
| Nov 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $50.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $50.00 |
| Nov 5, 2024 | Wedbush | Yun Zhong | Outperform | Initiates | $58.00 |
Protagonist Therapeutics Inc. (PTGX) Competitors
The following stocks are similar to Protagonist based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Protagonist Therapeutics Inc. (PTGX) Financial Data
Protagonist Therapeutics Inc. has a market capitalization of $2.71B with a P/E ratio of 56.1x. The company generates $207.80M in trailing twelve-month revenue with a 27.0% profit margin.
Revenue growth is -88.9% quarter-over-quarter, while maintaining an operating margin of -68.2% and return on equity of +9.0%.
Valuation Metrics
Market Cap
$2.71B
Enterprise Value
$2.15B
P/E Ratio
56.1x
PEG Ratio
-30.6x
Price/Sales
13.1x
Growth & Margins
Revenue Growth (YoY)
-88.9%
Gross Margin
N/A
Operating Margin
-68.2%
Net Margin
+27.0%
EPS Growth
-88.9%
Financial Health
Cash/Price Ratio
+20.9%
Current Ratio
17.3x
Debt/Equity
1.6x
ROE
+9.0%
ROA
+2.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Protagonist Therapeutics Inc. (PTGX) Business Model
About Protagonist Therapeutics Inc.
What They Do
Develops peptide-based therapeutics for serious health disorders.
Business Model
Protagonist Therapeutics Inc. operates a biopharmaceutical model focused on discovering and developing peptide-based therapeutics. The company generates revenue through the advancement of its drug candidates, which target diseases with significant unmet medical needs. By utilizing a proprietary technology platform, they aim to create innovative treatments that improve patient outcomes, potentially leading to partnerships, licensing agreements, or product sales in the biotechnology market.
Additional Information
Located in Newark, California, Protagonist Therapeutics is actively contributing to advancements in the biotechnology industry. Their research efforts are directed at addressing critical diseases like inflammatory bowel disease and myeloproliferative neoplasms, positioning them as a key player in the healthcare sector with the potential for impactful new therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
126
CEO
Dr. Dinesh V. Patel Ph.D.
Country
United States
IPO Year
2016
Website
www.protagonist-inc.comProtagonist Therapeutics Inc. (PTGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Protagonist Therapeutics announced positive Phase 3 results for rusfertide in polycythemia vera and icotrokinra in psoriasis. The company has $697.9M in cash, ensuring funding through at least 2028.
Why It Matters
Successful trial results and upcoming presentations indicate strong potential for rusfertide and icotrokinra, enhancing investor confidence and likely driving stock value. Significant cash reserves support future growth.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Protagonist Therapeutics (PTGX) reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a $0.50 loss, down from earnings of $3.26 per share last year.
Why It Matters
Protagonist Therapeutics' smaller-than-expected loss indicates improved financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
23 days ago
Quick Summary
Protagonist Therapeutics will present an abstract at the ASCO Annual Meeting from May 30 to June 3, 2025, highlighting potential developments in their research.
Why It Matters
Protagonist Therapeutics' acceptance at ASCO could enhance visibility, attract potential investors, and influence stock performance based on clinical trial results.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Protagonist Therapeutics granted an equity inducement award to a new employee on April 15, 2025, under its Amended and Restated 2018 Inducement Plan.
Why It Matters
Protagonist Therapeutics' equity inducement award signals potential growth and talent acquisition, which may enhance innovation and drive future stock value, impacting investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Protagonist Therapeutics (PTGX) has a consensus price target indicating a 27.4% upside potential, supported by an upward trend in earnings estimate revisions.
Why It Matters
A 27.4% upside potential in Protagonist Therapeutics suggests significant growth opportunity, especially with rising earnings estimate revisions indicating positive market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Protagonist Therapeutics has been named in Fast Company's 2025 list of the World's Most Innovative Companies, recognizing its advancements in peptide-based therapeutics.
Why It Matters
Protagonist Therapeutics' recognition on Fast Company's list enhances its visibility, potentially attracting investors and partners, and signaling confidence in its innovative pipeline.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About PTGX Stock
What is Protagonist Therapeutics Inc.'s (PTGX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Protagonist Therapeutics Inc. (PTGX) has a median price target of $69.00. The highest price target is $82.00 and the lowest is $41.00.
Is PTGX stock a good investment in 2025?
According to current analyst ratings, PTGX has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTGX stock?
Wall Street analysts predict PTGX stock could reach $69.00 in the next 12 months. This represents a 55.4% increase from the current price of $44.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protagonist Therapeutics Inc.'s business model?
Protagonist Therapeutics Inc. operates a biopharmaceutical model focused on discovering and developing peptide-based therapeutics. The company generates revenue through the advancement of its drug candidates, which target diseases with significant unmet medical needs. By utilizing a proprietary technology platform, they aim to create innovative treatments that improve patient outcomes, potentially leading to partnerships, licensing agreements, or product sales in the biotechnology market.
What is the highest forecasted price for PTGX Protagonist Therapeutics Inc.?
The highest price target for PTGX is $82.00 from at , which represents a 84.6% increase from the current price of $44.41.
What is the lowest forecasted price for PTGX Protagonist Therapeutics Inc.?
The lowest price target for PTGX is $41.00 from Julian Harrison at BTIG, which represents a -7.7% decrease from the current price of $44.41.
What is the overall PTGX consensus from analysts for Protagonist Therapeutics Inc.?
The overall analyst consensus for PTGX is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $69.00.
How accurate are PTGX stock price projections?
Stock price projections, including those for Protagonist Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 11:48 AM UTC